The Massachusetts biotech industry rebounded in 2024. Can the momentum last?

This column is from Trendlines, The Boston Globe’s business newsletter that covers the forces shaping the economy in Boston and beyond. If you’d like to receive it via email on Mondays and Thursdays, sign up here.

Anticipation was in the air last January as biotechnology executives, analysts, and investors convened in San Francisco for the annual J.P. Morgan Healthcare Conference. After a couple of brutal years, the industry — a pillar of the Massachusetts economy — seemed poised for a rebound.

The optimism wasn’t misguided.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

AI technology transforms hair analysis for health diagnostics and forensics

A new application that uses artificial intelligence may revolutionize the way scientists study hair and could lead to the development of health diagnostics based solely

September 5, 2024

Produce prescription programs could save US healthcare system $40 billion

An apple a day not only keeps the doctor away, it also could save the United States at least $40 billion in medical bills, report

July 7, 2023

Aerobic exercise boosts cognitive function in breast cancer patients

Many women who receive chemotherapy experience a decreased ability to remember, concentrate, and/or think-;commonly referred to as “chemo-brain” or “brain fog”-;both short- and long-term.

October 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.